Switching from one generic alendronate to another - a common procedure in Poland in the years 2001-2005 by Franek, Edward et al.
14
PRACE ORYGINALNE/ORIGINAL PAPERS
Endokrynologia Polska/Polish Journal of Endocrinology
Tom/Volume 62; Numer/Number 1/2011
ISSN 0423–104X
Prof. Edward Franek MD, Department of Internal Medicine, Endocrinology and Diabetology, Central Clinical Hospital MSWiA,
Wołoska St. 137, 02–507 Warszawa, tel.: +48 22 508 14 05, fax: +48 22 508 14 00, e-mail: edward.franek@cskmswia.pl
Switching from one generic alendronate to another
— a common procedure in Poland in the years 2001–2005
Częste zmiany leku z jednego alendronianu na drugi
w Polsce w latach 2001–2005
Edward Franek1,2, Marek Tałałaj3, Hanna Wichrowska1, Beata Czerwieńska4, Rafał Filip5,
Krzysztof Safranow6, Ewa Marcinowska-Suchowierska3, Andrzej Więcek4
1Department of Internal Diseases, Endocrinology and Diabetology, CSK MSWiA, WarszawaWarsaw, Poland
2Department of Endocrinology, Medical Research Center, Polish Academy of Sciences, WarszawaWarsaw, Poland
3Department of Internal Diseases, Postgraduate Medical School, Warszawa, Poland
4Department of Nephrology, Endocrinology and Metabolic Diseases, Medical University of Silesia in Katowice, Poland
5Department of Bone Metabolic Disease, Institute of Agricultural Medicine, Lublin, Poland
6Department of Biochemistry and Medical Chemistry, Pomeranian Medical University, Szczecin, Poland
Abstract
Introduction: In clinical ambulatory practice, patients often, rather than discontinuing treatment, change to another one. This study aims
to assess the reasons why patients with osteoporosis switch from one alendronate to another with a different brand name.
Material and methods: A retrospective analysis of 747 bisphosphonate-treated patients was performed (651 female, average age 67.3 ± 8.9 years,
BMI 26.5 ± 4.0 kg/m2). The frequency and reasons for drug switching during the 19.4 ± 13.4 months of observation were analysed.
Results: In 387 (51.8%) patients, treatment was not changed during the observation period, whereas in 360 (48.2%) patients, at least one
drug switch occurred. Almost 40% of patients from that group (138 patients) switched from one alendronate to another alendronate with
a different brand name. The most frequent reasons were: adverse event (36.9%), high price of the drug (23.2%) and request of patient
(16.7%).
Conclusions: A substantial proportion of persistent bisphosphonate-treated patients switch treatment from one alendronate to another.
The most frequent reasons for that kind of switching are the occurrence of an adverse event and the high cost of treatment.
(Pol J Endocrinol 2011; 62 (1): 14–17)
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Streszczenie
Wstęp: W praktyce lekarskiej pacjenci ambulatoryjni raczej zmieniają leczenie, niż zaprzestają go w ogóle. Niniejsze badanie miało na
ceku ocenę powodów, z jakich pacjenci chorzy na osteoporozę zmieniają jeden preparat alendronianu na drugi o innej nazwie.
Materiał i metody: Przeprowadzono retrospektywną analizę 747 chorych leczonych bisfosfonianami (651 kobiet, średni wiek 67,3 ± 8,9 lat,
BMI 26,5 ± 4,0 kg/m²). Analizowano częstość i powody zmian leków w trakcie obserwacji przez 19,4 ± 13,4 miesięcy.
Wyniki: U 387 (51,8%) chorych leczenie nie było zmieniane w trakcie obserwacji, podczas gdy u pozostałych 360 (48,2%) leki zmieniano
przynajmniej raz. Prawie 40% chorych z tej grupy (138) zmieniło leczenie z jednego alendronianu na drugi, o innej nazwie. Najczęstszymi
powodami takiej zmiany były: działania niepożądane (36,9%), wysoka cena leku (23,2%) i prośba chorego (16,7% zmian).
Wnioski: Znaczny odsetek leczonych bisfosfonianami chorych zmienia leczenie z jednego alendronianu na drugi. Najczęstszymi przy-
czynami takich zmian było wystąpienie objawów niepożądanych i wysoki koszt leku. (Endokrynol Pol 2011; 62 (1): 14–17)
Słowa kluczowe: osteoporoza, alendronian, stosowanie się do zaleceń lekarskich, zmiana leku
Introduction
To achieve the main aim of osteoporotic treatment, i.e.
a reduction of incident fractures, long-term pharmaco-
logical treatment is necessary. However, even during
short treatment periods it is not easy to achieve proper
adherence to the therapy. Many patients are either non-
compliant, or non-persistent, or both [1]. In such pa-
tients, treatment is suboptimal and the risk of bone frac-
ture is increased [2]. Therefore, another consequence
of poor adherence is an increase in healthcare costs [3].
There is a great deal of published data relating to
non-adherence, most of which comes from prospective,
pre-designed clinical trials. For example, it has been
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shown that in Poland more than 20% of post-menopausal
women discontinue bisphosphonate treatment within
18 months of its initiation [4]. In clinical practice howev-
er, if patients are not compliant or persistent for any rea-
son, they are usually encouraged by the treating physi-
cian to restart the drug or to start another drug in order
to achieve the optimal adherence [5]. That means that
many patients do not stop the treatment, but change it.
Our study aimed to re-analyse data from the previ-
ous trial [5], focusing on switching from one alendronate
to another with a different brand, in order to assess the
reasons for that switch, and the differences between
switchers and non-switchers.
Material and methods
Seven hundred and forty seven alendronate-treated
patients (from the 1,314 patients assessed retrospectively
in four osteoporosis centres in Poland) were included
in the analysis, the mean age of the group being 67.4 ±
± 8.9 years and the BMI 26.5 ± 4.0 kg/m2.
Neither the presence of ‘osteoporosis’ according to
the WHO definition (T-score < –2.5), nor the risk of frac-
ture, were predefined as inclusion/exclusion criteria.
Bone mineral density (BMD) results were therefore not
recorded. Every change of medication and the reasons
for it were recorded. The latter were classified as: ad-
verse events, treatment failure, therapy cost being too
high, patient request, the switch being made in another
outpatient clinic or hospital, treatment success, or an
overlong (in a physician’s opinion) period of therapy.
Treatment failure (as defined by the treating physician),
was occurrence of osteoporotic fracture, a significant
decrease of BMD, or an inadequate decrease of bone
turnover markers. Treatment success was mostly de-
fined as an increase of BMD. In participating centres,
BMD was assessed by dual-energy X-ray absorptiome-
try (DXA)  and spine and proximal femur measure-
ments. Bone markers used for monitoring varied from
centre to centre.
During the study period, daily alendronate was the
only bisphosphonate reimbursed in Poland. Therefore
no switches from daily to weekly alendronate were re-
corded. In assessed patients, seven different alendr-
onate generics were used.
Statistical analysis
Statistical significance of differences between groups
was calculated using the Kruskal-Wallis test (for com-
parison of three groups) and the Mann-Whitney test
(for comparison of two groups) for quantitative vari-
ables. For comparison of qualitative variables, the c2 test
or Fisher’s exact test was used. Data is presented as
mean ± SD or number (percentage).
Results
Some 48.2% of all patients made at least one switch of
their osteoporosis treatment during the observation
period. Almost 40% of patients from the switching
group (138 patients, 38.3%) changed treatment from one
alendronate to another with a different brand name.
Switches occurred from the original brand to a generic
drug (32.1%), the reverse (16%), as well as from one
generic drug to another (51.9%). 54.8 % of switches were
made from the original branded drug to a generic drug
because of the high cost of treatment, but 45.2% of high
cost switches included switching between generic
drugs. A comparison of the basal data of switchers vs.
non-switchers is shown in Table I. They differed signif-
icantly only in regard to the time of observation, which
was slightly longer in both switchers’ groups.
Table I. Basal characteristics of patients
Tabela I. Podstawowe dane pacjentów
Parameter Non-switchers Switchers to alendronate Switchers to another p*
n = 387  n = 138  treatment n = 222
Age 66.9 ± 8.9 67.9 ± 9.4 67.8 ± 8.6 0.21 (NS)
Gender 340 F/47 M 119 F/19 M 192 F/30 M 0.83 (NS)
BMI 26.6 ± 4.0 26.9 ± 4.4 25.9 ± 3.8^ 0.071
Fractures at baselinea 113/346 (32.7%) 43/109 (39.4%) 50/139 (36.0%) 0.40 (NS)
Time of observation 16.6 ± 8.5 20.1 ± 13.3# 23.7 ± 18.4# < 0.0001
Time to the first switch – 9.6 ± 9.7 10.8 ± 10.8 0.45 (NS)
Calcium/Vit. D supplementationa 345/354 (97.5%) 110/112 (98.2%) 146/148 (98.6%) 0.67 (NS)
*Statistical significance of differences among three groups; Kruskal-Wallis test was used for quantitative variables and c2 test for qualitative variables;
^p < 0.05 for difference in comparison to switchers for alendronate group (Mann-Whitney test); #p<0.05 for difference in comparison to non-
switchers group (Mann-Whitney test); aData missing in some patients; percentage calculated for patients from data available
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Reasons why alendronate treated patients switch to
another treatment (the ‘first switch’) are shown in Ta-
ble II. Adverse events more often resulted in a switch to
a treatment other then alendronate. However, they also
caused a surprisingly frequent (in 36.9% of switchers)
switch to another alendronate. High drug cost and the
request of the patient were the most frequent reasons
for alendronate-alendronate switching, whereas treat-
ment failure and a switch made in another centre took
place with similar frequency in both groups (Table II).
Discussion
The only data in the literature relating to the switching
of bisphosphonates deals with switching from daily to
weekly bisphosphonates [6]. There has been no study
regarding switches to the same drug with a different
brand. A possible reason for this is that most published
data originates from countries in the west, where os-
teoporotic patients are rarely treated with generic drugs,
although in the USA generic drugs now account for 63%
of all prescriptions [7]. Generic antiosteoporotic drugs
are frequently marketed in Eastern European countries
and in the developing world. It is therefore possible that
the published data does not reflect the situation in
a large part of the world.
Most osteoporotic patients in Poland are treated with
bisphosphonates. The most important reason for that
is that alendronate is the only bisphosphonate and the
only anti-fracture drug reimbursed in Poland. This is
the main reason for replacing any initial therapy with
alendronate in more than 50% of patients [5] who could
not afford the former treatment.
 It was expected that this would also be the main
reason for switches from alendronate to the same alen-
dronate, but one manufactured under a different com-
mercial name. However, surprisingly, the commonest
reason for that kind of switch was an adverse event.
Although a more common reaction if an adverse event
occurred was a switch to another drug (Table II), in
many cases (probably for financial reasons), the only
possible action that did not leave the patient untreated
was to undertake a purely psychological action, and to
switch to another alendronate with a different brand.
Such an action was probably made in the hope that if
the adverse event was in fact not drug-related, the pa-
tient, who rarely looks at chemical names, will not ex-
pect the same adverse event, as he or she would do if
restarting a drug with the same brand name.
The high cost of the drug was the second most fre-
quent reason for switching to another alendronate
(Table II). More than 50% of switches made because of
the treatment cost were switches from the original brand
to a generic drug. However, the remaining 45.2% of
switches because of high cost occurred between differ-
ent generic drugs, something which proves that there is
also price competition between different generic brands.
A relatively high number of switchers from one al-
endronate to another changed their treatment at their
own request (16.7% of all switches). Taking into account
that only 23.2% changed their treatment because of the
cost, it also seems possible that patients are unwilling
to admit that they cannot afford the given treatment.
Further research is required into the reasons behind
a treatment switch at the request of the patient.
This study has some limitations. As in any study,
patient selection may be specifically biased. Multi-cen-
tre design was employed to minimise this limitation.
Another limitation is that only the 10 mg daily alen-
dronate treatment was analysed, whereas now 70 mg
weekly alendronate is used in most patients. Taking into
account, however, that frequency of adverse events af-
ter weekly alendronate treatment may be similar [8] and
that four different brands of 70 mg alendronate with
different prices are marketed in Poland, we believe that
the described mechanisms remain the same.
Table II. Reasons for the switch from one generic alendronate to antoher one to another treatment
Tabela II. Powody zamiany jednego preparatu alendronianu na inny preparat lub na inny lek
Reasons for the first switch All switchers Switchers to alendronate Switchers to another treatment p*
Adverse event 173 (48.0%) 51 (36.9%) 122 (54.9%) 0.0011
Treatment failure 41 (11.4%) 15 (10.9%) 26 (11.7%) 0.86 (NS)
High cost 36 (10.0%) 32 (23.2%) 4 (1.8%) < 0.0001
Request of patient 37 (10.3%) 23 (16.7%) 14 (6.3%) 0.0022
Switch made in another centre 44 (12.2%) 13 (9.4%) 31 (14.0%) 0.25 (NS)
Treatment success 29 (8.1%) 4 (2.9%) 25 (11.3%) 0.0046
Total 360 (100%) 138 (100%) 222 (100%) –
*Statistical significance of differences between switchers to alendronate and switchers to another treatment (Fisher’s exact test)
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A third limitation is that the retrospective study de-
sign may bias the results and make a precise answer to
many questions impossible. In a prospective study,
however, the assessed behaviour of patients and doc-
tors and the results may also be biased by awareness of
the study procedure.
Conclusions
In summary, our results suggest that if alendronate
manufactured by different companies with different
brands is available on the market, many persistent bis-
phosphonate-treated patients switch treatments from
one alendronate to another. The most frequent reasons
for that kind of switching are the occurrence of an ad-
verse event and the high cost of the treatment.
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